Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000212379 | SCV000210925 | uncertain significance | not provided | 2020-10-16 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as a pathogenic or benign germline variant to our knowledge; This variant is associated with the following publications: (PMID: 29156750) |
Ambry Genetics | RCV000160396 | SCV000213717 | likely benign | Hereditary cancer-predisposing syndrome | 2021-11-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000168234 | SCV000218903 | likely benign | Hereditary diffuse gastric adenocarcinoma | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000168234 | SCV000785806 | uncertain significance | Hereditary diffuse gastric adenocarcinoma | 2017-12-05 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000212379 | SCV000888028 | uncertain significance | not provided | 2018-07-31 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000160396 | SCV000903422 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-05-05 | criteria provided, single submitter | clinical testing | This missense variant replaces aspartic acid with asparagine at codon 676 of the CDH1 protein. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast cancer in the literature (PMID: 25186627). This variant has been identified in 6/282868 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
European Reference Network on Genetic Tumour Risk Syndromes |
RCV000168234 | SCV003926879 | uncertain significance | Hereditary diffuse gastric adenocarcinoma | 2022-08-01 | criteria provided, single submitter | clinical testing | Not applicable criteria (PMID: 30311375) |
Myriad Genetics, |
RCV000168234 | SCV004019587 | uncertain significance | Hereditary diffuse gastric adenocarcinoma | 2023-03-06 | criteria provided, single submitter | clinical testing | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. |
Baylor Genetics | RCV003462089 | SCV004215640 | uncertain significance | Familial cancer of breast | 2024-01-15 | criteria provided, single submitter | clinical testing |